Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Glycotest

Glycotest
2012 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series A LATEST DEAL TYPE
$10M LATEST DEAL AMOUNT
2 INVESTORS
Description

Operator of a liver diagnostics company intended to commercialize new and unique blood tests for life-threatening liver cancers and fibrosis-cirrhosis. The company employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay technology that exploit novel sugar-based disease signal chemistry, enabling patients with serious liver disease with novel clinical laboratory testing services.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Primary Office
  • 77 Water Street, Suite 817
  • Suite 817
  • New York, NY 10005
  • United States

+1 (646) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Glycotest’s full profile, request a free trial.

Glycotest Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Corporate (Series A) 05-Feb-2019 $10M 0000 000.00 Completed Clinical Trials - Phase 3
3. Buyout/LBO 31-Dec-2016 00.000 00.00 00.000 Completed Generating Revenue
2. Later Stage VC 25-May-2012 $801K $1.3M Completed Stealth
1. Accelerator/Incubator 05-Jun-2012 $500K $500K Completed Stealth
To view this company’s complete deal history including valuation and funding, request access »

Glycotest Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 000
To view this company’s complete Cap Table, request access »

Glycotest Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Fuji Corporation Matsuyama, Japan 0000
0000 Corporation Enid, OK 00
To view this company’s complete list of competitors, request access »

Glycotest Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Fosun Pharma Corporation Minority 000 0000 000000 0
NetScientific Venture Capital Majority 000 0000 000000 0

Glycotest Executive Team (3)

Name Title Board
Seat
Contact
Info
Lawrence Cohen Chief Executive Officer & Board Member
Charles Swindell Ph.D Chief Operating Officer & Chief Scientific Officer
Anand Mehta Ph.D Chief Technology Officer, Innovator & Advisor

Glycotest Board Members (8)

Name Representing Role Since Contact
Info
Ian Postlethwaite NetScientific Board Member 000 0000
Joel Zhang Fosun Pharma Board Member 000 0000
Lawrence Cohen Glycotest Chief Executive Officer & Board Member 000 0000
Steve Smith NetScientific Chairman 000 0000
Yu Jing Fosun Pharma Board Member 000 0000

3 Former Board Members

You’re viewing 5 of 8 board members. Get the full list »